2 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
Follow EGFR Mutation: new trials by email Literature Review of EGFR Mutation trials Research Report on EGFR Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer Gefitinib and Pemetrexed/platinum, Gefitinib mono-therapy - Non-small Cell Lung Cancer, Brain Metastases | Phase 3 | Unknown | Sun Yat-sen University | 160 | 2016-01-01 | 2022-03-08 |
| Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC Erlotinib - NSCLC, EGFR Mutation | Phase 3 | Unknown | The First Affiliated Hospital of Guangzhou Medical University | 220 | 2013-08-01 | 2015-02-12 |
Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1)
Brain Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Erlotinib Hydrochloride (1) · Gefitinib (1) · Pemetrexed (1) · Platinum (1)
Sun Yat-sen University (1) · The First Affiliated Hospital of Guangzhou Medical University (1)
China (2)